2012 ESC STEMI guidelines and reperfusion therapy: Evidence base ignored, threatening optimal patient management

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation


Published Version
doi:10.1136/heartjnl-2013-304117

Citable link

http://nrs.harvard.edu/urn-3:HUL.InstRepos:11717609

Terms of Use

This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
2012 ESC STEMI guidelines and reperfusion therapy

Evidence base ignored, threatening optimal patient management

Christian Juhl Terkelsen, Duane S Pinto, Holger Thiele, Peter Clemmensen, Kjell Nikus, Jens Flenssted Lassen, David Hildick-Smith, Evald Høj Christiansen, Hans Aarøe, Hans Henrik Tilsted Hansen, Goran Stankovic, Anders Junker, Georgios Sianos, Göran Olivecrona, Hans Erik Botker, Charles Michael Gibson, Eric Boersma

The 2012 European Society of Cardiology (ESC) ST-Elevation Myocardial Infarction (STEMI) guideline acknowledges that STEMI patients should receive reperfusion therapy as soon as possible, and that prehospital fibrinolysis or field-triage directly to Primary Percutaneous Coronary Intervention (PPCI) centres is the preferred reperfusion strategy. However, when recommending fibrinolytic therapy (FT) within 30 min from First Medical Contact (FMC), if PPCI cannot be performed ‘within 60 min of FMC in patients presenting early, with a large amount of myocardium at risk’, the guidelines imply that only 30 min extra may be expended to perform PPCI instead of administering FT (‘PCI-related delay’) (figure 1).

Throughout the years, successive guidelines have mistakenly equated ‘PCI-related delay’ and ‘FMC to PPCI’ (the total delay from FMC to PPCI) (figure 1). This error persists in the recently updated ESC guideline. Clarification of this distinction is of paramount importance because of the suggested reduction in the ‘window of opportunity for PPCI’, a suggestion not clearly supported by evidence, which has significant public health implications. In paragraph 3.5.2, the ESC STEMI guideline references a registry analysis from the National Registry of Myocardial Infarction (NRMI), concluding: ‘primary PCI (wire passage) should be performed within 90 min after FMC in all cases. In patients presenting early, with a large amount of myocardium at risk, the delay should be shorter (<60 min)’. The NRMI reference is also listed in paragraph 3.4.1 in the ESC STEMI guideline when recommending the acceptable ‘FMC-to-PCI’ delay of only 60 min in early incomers with anterior infarction. However, this study describes ‘PCI-related delay’, that is, the theoretical extra delay that may be spent to perform PPCI over FT (figure 1). The NRMI manuscript by Pinto et al. does not describe ‘FMC-to-PCI’ delay in the cohorts evaluated since timing of Emergency Medical Service (EMS) evaluation was imprecise. The only delay data available were the interval ‘Door-to-balloon (D2B)’ delay, which was 116 min when calculated as a weighted mean (table 1). Given the fact that ‘FMC-to-PCI’ is considerably longer than D2B delay among patients transported by EMS (figure 1), the ‘FMC-to-PCI’ delay is likely to have been considerably longer than 120 min (table 1). Consequently, these data cannot be applied recommendations regarding the optimal time to ‘FMC to PCI’ or to support a recommendation of ‘of a systems goal of FMC to PCI of 60 min.’ It would appear that the 2012 STEMI guideline authors, when compiling the overwhelming amount of scientific data, have either intended to use a different reference or misinterpreted the findings from Pinto et al’s original work. We are not aware of supportive data that would justify the current STEMI guideline recommendations to consider fibrinolysis within 30 min of FMC when PPCI cannot be performed within 60 min of FMC.

There have been several other studies addressing the optimal ‘PCI-related delay’. The initial study by Pinto and colleagues was limited by the fact that optimal FT (fibrin-specific drugs) was compared with a less-than-optimal PPCI strategy (PPCI centres performing only a mean of 20 PPCI procedures a year). A later analysis by Pinto and colleagues found an acceptable ‘PCI-related delay’ of approximately 120 min without any excessive mortality in PPCI-treated patients with anterior infarction or short symptom duration, even at a PCI-related delay of approximately 120 min. While the magnitude of survival difference between PPCI and FT decreased as delay to PCI increased, no point did mortality for PPCI exceed that with FT. These findings are concordant with the previous findings by Boersma and colleagues that were based on individual data from studies comparing FT with PPCI. Swedish registry data indicate a comparable outcome from PPCI and FT, even with a PCI-related delay of 240 min, and observations from both the French FAST-MI registry and the Vienna registry report comparable outcomes for patients treated with FT and PPCI with a PCI-related delay of 90 min.

The ESC STEMI guideline also relies upon analysis of the Comparison of Angioplasty and Pre-hospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) trial when recommending a ‘FMC-to-PPCI’ delay of 60 min. This non-prespecified subgroup analysis, based on 460 patients, claimed a lower mortality in patients randomised to FT versus PPCI among subjects presenting early. However, this finding did not reach statistical significance. A much larger meta-analysis including individual data from 6763 patients demonstrated superiority of PPCI over FT, in early as well as late incomers. This finding was also confirmed in the Swedish registry data. It seems that the aforementioned subgroup analysis from CAPTIM was weighted too heavily. Furthermore, findings from the CAPTIM substudy offer little value in substantiating a recommendation of ‘FMC to PCI’ of <60 min,
when the ‘FMC to PPCI’ delay must have been at least 100 min in the trial. The time from symptom onset to randomisation was 108 min in the CAPTIM trial, and the time to PPCI was 190 min, indicating that time from randomisation to PPCI was 82 min. The response time (EMS call to arrival on scene) is typically about 10 min, and the ambulance physicians must have used at least 10 min on scene before randomisation. A conservative estimate, thus, is a ‘FMC to PPCI’ delay of at least 102 min in this study. Consequently, neither the CAPTIM trial nor the NRMI analyses support a ‘FMC to PPCI’ delay of <60 min.

Creation of a clinical guideline is an immense task, and we commend the writing group for their efforts in creating a comprehensive and useful document summarising the available scientific data informing management of STEMI patients. The guidelines serve as a valuable resource, but the flow charts and suggestions may be more applicable for new STEMI networks in regions without previously established systems of care. For well-functioning STEMI networks, we believe that the best available evidence supports a PCI-related delay <120 min. If existing STEMI networks were to implement the shorter metrics introduced in the current guidelines, there is a risk of FT administration to patients where outcomes would be better with PPCI.

Finally, in regions with an ideal STEMI systems of care, with prehospital diagnosis and field-triage directly to large-volume PPCI centres, FMC is variably defined as time of EMS call or EMS arrival on scene. In regions that do not use prehospital diagnosis, FMC is simply the time of ambulance arrival at the hospital. In self-presenters, FMC is also time of arrival at the hospital according to regional STEMI system of care.

Table 1 Delays to PPCI observed in the references used for recommendation of a First Medical Contact (FMC) to PPCI delay below 60 min in the recent European Society of Cardiology 2012 STEMI-guidelines

<table>
<thead>
<tr>
<th>References</th>
<th>Emergency medical service call to arrival on scene</th>
<th>On scene delay</th>
<th>Transport delay</th>
<th>Door-to-balloon delay (D2B)</th>
<th>Overall ‘FMC to PPCI’ delay</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pinto et al</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>116 min*</td>
<td>NA but &gt;&gt;&gt;D2B delay!</td>
</tr>
<tr>
<td>Steg et al</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA but at least 102 min</td>
</tr>
</tbody>
</table>

*In the Pinto et al reference D2B delays were presented for four groups varying from 91 to 179 min. The weighted mean D2B delay is presented here.
†None of the many papers from the CAPTIM trial have presented ‘FMC to PPCI’ delay. Time to PPCI was 190 min and time to randomisation was 108 min. Adding 10 min for emergency medical service response time and just 10 min on scene before randomisation, this would add up to a cumulative ‘FMC to PPCI’ delay of approximately 102 min.

When comparing regions based on observed ‘FMC to PPCI’ delays, it may erroneously seem that regions rightfully performing inferiorly with regards to regions that are not implementing prehospital diagnosis, while the opposite is likely the case. In fact, if one were to incorporate current ESC guideline recommendations of ‘FMC to PPCI delay below 60 min’, in regions using prehospital diagnosis for field-triage to PCI centres with rapid treatment times, FT would be administered to more patients compared with regions without prehospital diagnosis even though total ischaemic times would have been shorter for the patients, or even more absurdly, regions could eliminate prehospital diagnosis, increasing the ‘window of opportunity’ for PPCI.

We recommend that for future guidelines, professional societies on both sides of the Atlantic acknowledge the current confusion about the terminologies on treatment delays in STEMI and uncertainties in utilising available data for information regarding the proper treatment for various patient subsets, and avoid recommendations that may have deleterious consequences. It is uncertain whether a pharmacoinvasive strategy in the future will qualify as an alternative reperfusion strategy. However, the Strategic Reperfusion Early After Myocardial Infarction trial found no mortality benefit but an increased risk of stroke in patients randomised to a pharmacoinvasive strategy compared to patients randomised to a PCI strategy.10

Author affiliations
1Department of Cardiology, Aarhus University Hospital in Skejby, Aarhus, Denmark
2Department of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
3Department of Cardiology, University of Leipzig-Heart Center, Leipzig, Germany
4Department of Cardiology, Rigshospitalet, Copenhagen, Denmark
5Department of Cardiology, Heart Center, Tampere University Hospital, Tampere, Finland
6Department of Cardiology, Sussex Cardiac Centre, Brighton and Sussex University Hospitals, Brighton, UK
7Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark
8Department of Cardiology, Clinical Center of Serbia and Medical School of Belgrade, Belgrade, Serbia
9Department of Cardiology, Odense University Hospital, Odense, Denmark
10Department of Cardiology, AHEPA University Hospital, Thessaloniki, Greece
11Department of Cardiology, Skane University Hospital, Lund, Sweden
12Department of Cardiology, Erasmus Medical Centre, Rotterdam, Netherlands
Contributors CJT, EB and DSP made the first draft of the viewpoint. All coauthors critically revised the viewpoint, agreed on its content and accepted it for publication.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES


